» Articles » PMID: 35172971

Risks of Mental Health Outcomes in People with Covid-19: Cohort Study

Overview
Journal BMJ
Specialty General Medicine
Date 2022 Feb 17
PMID 35172971
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To estimate the risks of incident mental health disorders in survivors of the acute phase of covid-19.

Design: Cohort study.

Setting: US Department of Veterans Affairs.

Participants: Cohort comprising 153 848 people who survived the first 30 days of SARS-CoV-2 infection, and two control groups: a contemporary group (n=5 637 840) with no evidence of SARS-CoV-2, and a historical control group (n=5 859 251) that predated the covid-19 pandemic.

Main Outcomes Measures: Risks of prespecified incident mental health outcomes, calculated as hazard ratio and absolute risk difference per 1000 people at one year, with corresponding 95% confidence intervals. Predefined covariates and algorithmically selected high dimensional covariates were used to balance the covid-19 and control groups through inverse weighting.

Results: The covid-19 group showed an increased risk of incident anxiety disorders (hazard ratio 1.35 (95% confidence interval 1.30 to 1.39); risk difference 11.06 (95% confidence interval 9.64 to 12.53) per 1000 people at one year), depressive disorders (1.39 (1.34 to 1.43); 15.12 (13.38 to 16.91) per 1000 people at one year), stress and adjustment disorders (1.38 (1.34 to 1.43); 13.29 (11.71 to 14.92) per 1000 people at one year), and use of antidepressants (1.55 (1.50 to 1.60); 21.59 (19.63 to 23.60) per 1000 people at one year) and benzodiazepines (1.65 (1.58 to 1.72); 10.46 (9.37 to 11.61) per 1000 people at one year). The risk of incident opioid prescriptions also increased (1.76 (1.71 to 1.81); 35.90 (33.61 to 38.25) per 1000 people at one year), opioid use disorders (1.34 (1.21 to 1.48); 0.96 (0.59 to 1.37) per 1000 people at one year), and other (non-opioid) substance use disorders (1.20 (1.15 to 1.26); 4.34 (3.22 to 5.51) per 1000 people at one year). The covid-19 group also showed an increased risk of incident neurocognitive decline (1.80 (1.72 to 1.89); 10.75 (9.65 to 11.91) per 1000 people at one year) and sleep disorders (1.41 (1.38 to 1.45); 23.80 (21.65 to 26.00) per 1000 people at one year). The risk of any incident mental health diagnosis or prescription was increased (1.60 (1.55 to 1.66); 64.38 (58.90 to 70.01) per 1000 people at one year). The risks of examined outcomes were increased even among people who were not admitted to hospital and were highest among those who were admitted to hospital during the acute phase of covid-19. Results were consistent with those in the historical control group. The risk of incident mental health disorders was consistently higher in the covid-19 group in comparisons of people with covid-19 not admitted to hospital versus those not admitted to hospital for seasonal influenza, admitted to hospital with covid-19 versus admitted to hospital with seasonal influenza, and admitted to hospital with covid-19 versus admitted to hospital for any other cause.

Conclusions: The findings suggest that people who survive the acute phase of covid-19 are at increased risk of an array of incident mental health disorders. Tackling mental health disorders among survivors of covid-19 should be a priority.

Citing Articles

Psychiatric and neuropsychiatric sequelae of COVID-19 within 2 years: a multinational cohort study.

Chai Y, Lam I, Man K, Hayes J, Wan E, Li X BMC Med. 2025; 23(1):144.

PMID: 40055683 PMC: 11887073. DOI: 10.1186/s12916-025-03952-z.


Review of organ damage from COVID and Long COVID: a disease with a spectrum of pathology.

Ewing A, Salamon S, Pretorius E, Joffe D, Fox G, Bilodeau S Med Rev (2021). 2025; 5(1):66-75.

PMID: 39974559 PMC: 11834749. DOI: 10.1515/mr-2024-0030.


History of Alcohol Use Disorder and Housing Instability as Predictors of Fatigue and Mental Health Problems During the COVID-19 Pandemic.

Leiter N, Luk J, Stangl B, Gunawan T, Schwandt M, Goldman D Prev Sci. 2025; 26(2):271-281.

PMID: 39932641 PMC: 11891101. DOI: 10.1007/s11121-025-01784-0.


Prevalence of depression, anxiety, and stress among students enrolled at King Khalid University: a cross-sectional study.

Al-Garni A, Shati A, Almonawar N, Alamri G, Alasmre L, Saad T BMC Public Health. 2025; 25(1):354.

PMID: 39875847 PMC: 11773868. DOI: 10.1186/s12889-025-21277-7.


Does SARS-CoV-2 Infection Increase Risk of Neuropsychiatric and Related Conditions? Findings from Difference-in-Differences Analyses.

Chen Y, Lu Y, Tong J, Zhang D, Chen J, Li L Res Sq. 2025; .

PMID: 39866876 PMC: 11760242. DOI: 10.21203/rs.3.rs-5621095/v1.


References
1.
Raker E, Zacher M, R Lowe S . Lessons from Hurricane Katrina for predicting the indirect health consequences of the COVID-19 pandemic. Proc Natl Acad Sci U S A. 2020; 117(23):12595-12597. PMC: 7293707. DOI: 10.1073/pnas.2006706117. View

2.
Xie Y, Bowe B, Al-Aly Z . Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun. 2021; 12(1):6571. PMC: 8589966. DOI: 10.1038/s41467-021-26513-3. View

3.
Xie Y, Bowe B, Gibson A, McGill J, Maddukuri G, Al-Aly Z . Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. JAMA Intern Med. 2021; 181(8):1043-1053. PMC: 8240007. DOI: 10.1001/jamainternmed.2021.2488. View

4.
Townsend E . COVID-19 policies in the UK and consequences for mental health. Lancet Psychiatry. 2020; 7(12):1014-1015. PMC: 7561293. DOI: 10.1016/S2215-0366(20)30457-0. View

5.
Cai M, Bowe B, Xie Y, Al-Aly Z . Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs. BMJ Open. 2021; 11(8):e047369. PMC: 8370839. DOI: 10.1136/bmjopen-2020-047369. View